Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a) (HER2-PREDICT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04257162
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : November 1, 2021
Daiichi Sankyo, Inc.
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 15, 2022
Estimated Study Completion Date : December 15, 2023